

SARS-COV-2 Spike RBD Protein (His & Avi), Biotinylated

General Information

Synonyms:	S protein RBD;S glycoprotein RBD;Spike protein RBD
Protein Construction:	Arg319-Asn532
Species:	SARS-CoV-2
Expression Host:	HEK293 Cells
Accession:	A0A6G7K2L4
Molecular Weight:	27 kDa (predicted). Due to glycosylation, the protein migrates to 36-40 kDa based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Immobilized Biotinylated SARS-COV-2 Spike RBD, His Tag at 1µg/ml (100µl/well) on the streptavidin precoated plate (5µg/ml). Dose response curve for Human ACE2, hFc Tag with the EC50 of 7.7ng/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1 EU/µg by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Shipping:

In general, Lyophilized powders are shipping with blue ice.

Protein Background

The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Reference

Larry J Anderson, Ralph S Baric. Emerging Human Coronaviruses - Disease Potential and Preparedness[J]. N Engl J Med, 2012, 367(19):1850-1852.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481